Tarsus Pharmaceuticals, Inc. Board of Directors

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Dr. Bobak R. Azamian M.D.

Dr. Bobak R. Azamian M.D.

Co-Founder, President, CEO & Chairman

Mr. Matthew Rossen M.B.A.

Mr. Matthew Rossen M.B.A.

Vice President of Marketing

Ms. Dianne C. Whitfield M.S.W.

Ms. Dianne C. Whitfield M.S.W.

Chief Human Resources Officer

Dr. Elizabeth Yeu M.D.

Dr. Elizabeth Yeu M.D.

Chief Medical Officer

Mr. Jeffrey S. Farrow CPA

Mr. Jeffrey S. Farrow CPA

CFO & Chief Strategy Officer

Mr. Scott Youmans

Mr. Scott Youmans

Vice President of Sales

Dr. Bryan Wahl J.D., M.D.

Dr. Bryan Wahl J.D., M.D.

General Counsel & Corporate Secretary

Ms. Adrienne Kemp

Ms. Adrienne Kemp

Senior Director of Corporate Communications

Mr. David Nakasone

Mr. David Nakasone

Head of Investor Relations

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.